Nasdaq
$1.21▼ 2.02%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $76.5MShares out 63.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
2- 10.5After-hours26.10.06 06:068-KKey event#●●●#●●●#●●●
Equillium, Inc.Bullish
Equillium has received approval from Australian regulatory authorities to initiate a Phase 1 clinical trial for EQ504. The company expects to begin dosing healthy participants by early November 2026.…more
$1.21-2.02%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.12Regular26.08.13 01:11SCHEDULE 13G/AOwnership
Equillium, Inc.
Adage Capital Management, L.P. updated its beneficial ownership stake in Equillium, Inc. in a filing dated August 12, 2026. This Schedule 13G/A document serves as an amendment to report changes in the investor's equity holdings.…more
$1.21-2.02%vs prev closeView filingShare
1 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.6After-hours26.10.07 05:05#●●●#●●●
Equillium Presents Preclinical Data for EQ504 at Immunology Conference
Equillium announced new preclinical data for its EQ504 program at the 50th Anniversary La Jolla Immunology Conference. As this is an early-stage research presentation, the impact on the company's valuation remains neutral.…more
$1.21-2.02%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.5After-hours26.10.06 05:05
●●●●●●●● ●●●●● ●●●●●●
Equillium has received regulatory approval in Australia to initiate a Phase 1 clinical trial for its autoimmune drug candidate, EQ504, with dosing expected to begin in early November. The study will evaluate safety and pharmacokinetics in healthy volunteers as a step toward developing the treatment for ulcerative colitis.…more
$1.21-2.02%vs prev close - 9.29After-hours26.09.30 05:05
●●●●●●●● ●●●●● ●●●●●●
Equillium announced new preclinical data for its ulcerative colitis candidate EQ504 at the 7th International AHR Conference. The findings highlight the drug's potential in immune regulation and epithelial barrier repair, though the program remains in early development.…more
$1.21-2.02%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report